Background: Therapeutic tolerance restoration has been proven to modify food
attributed to a failure to induce regulatory T cell (Treg)-mediated tolerance. [6] [7] [8] Patients suffering from polyendocrinopathy X-linked syndrome (IPEX) have a deficit in Tregs due to a mutation of the FOXP3 gene, causing a loss of tolerance with subsequent severe autoimmunity, food allergy, and infection. 9 In addition, Foxp3 polymorphism and differential epigenetic control of gene expression have been described in food allergic patients. [10] [11] [12] Remarkably, induction of Tregs is a critical marker of spontaneous resolution of food allergy 8, 13 and of successful specific disease-modifying immunotherapy. 14, 15 We have previously demonstrated in an IgE-mediated food allergy mouse model (that closely recapitulates food allergy in humans) that Tregs are reduced in sensitized animals and the adoptive transfer of these cells reversed mucosal inflammation and allergic immune responses. 16 We observed that the stepwise oral administration of cow 0 s milk proteins (CMP) to sensitized mice induced intestinal Tregs, which suppressed the Th2-mediated mechanisms (including IgE, cytokines, skin mast cell activation) and the clinical symptoms. Based on these findings, we were prompted to down-modulate clinical signs by sublingual administration of very low doses of CMP, compared to the doses administered by gavage.
A recent therapeutic approach for several immunological diseases (autoimmunity, GVHD, etc.) has been the in vivo or ex vivo expansion and transfer of Tregs [17] [18] [19] [20] using low doses of the T-cell growth factor IL-2. 21, 22 It has been therapeutically used in immunological disorders in human and experimental models [23] [24] [25] [26] [27] with differing degrees of success. 28, 29 Low doses of IL-2 increased in vivo the frequency of Tregs expressing the high-affinity IL-2 receptor (IL-2R), 30 and different strategies have been investigated to optimize its bioavailability. [31] [32] [33] In a pilot study using low doses of human IL-2 (25 000 IU), along with sublingual immunotherapy (10 ng of allergen), we failed to suppress hypersensitivity symptoms in animals that were intragastrically sensitized (unpublished results). Based on the fact that particular high-affinity anti-IL-2 monoclonal antibody improves IL-2 bioavailability and targets IL-2 (preferentially to CD25 on Tregs), [34] [35] [36] we next assessed the therapeutic potential of low doses of IL-2 (15 000 IU) combined with the monoclonal antibody (IL-2/anti-IL-2 complex; IL-2C) in the experimental model of food allergy. We found that the intraperitoneal administration of IL-2C successfully enhanced the tolerogenic mechanisms induced by very low doses of sublingual antigen and reversed food allergy.
| MATERIALS AND METHODS

| Reagents
Milk protein extract was prepared from skimmed dry milk (Svelty, Nestle The experimental design is shown in Figure S1 .
| Animal treatment
Sensitized mice were anesthetized and divided into 2 groups for sublingual (sl) treatment: a) mice receiving PBS sl and b) mice receiving 10 pg/4 lL of CMP sl twice a week during 4 weeks and 10 ng during the last 4 weeks. Groups were further divided in 2 subgroups for intraperitoneal treatment: (i) mice receiving PBS ip and (ii) mice receiving IL-2C ip ( Figure S1 ). Thirty minutes after the sl administration, mice were grouped and placed in clean cages to assure no cross-contamination between animals.
To characterize the mucosal induction of Tregs, mice received 175 lg/4 lL of CMP sl or PBS sl for 2 consecutive days, and thereafter, they received intraperitoneal injections of IL-2C for 3 consecutive days. Finally, mice were killed (day 5) and submaxillary lymph nodes (SLN) and sublingual mucosa were analyzed. 
| Ethics statement
| Cutaneous tests
Mice were injected with 20 lg of CMP in 20 lL of sterile saline in one footpad, and saline in the contralateral footpad (negative control), and later were injected intravenously (iv) with 100 lL of 0.1% Evans blue dye (Anedra, Buenos Aires, Argentina). The presence of blue color 10-20 minutes after the iv injection was considered a positive test and footpad swelling was measured with a digital micrometer.
2.6 | In vitro evaluation of the allergic reaction 2.6.1 | Serum-specific antibodies CMP-specific IgE was measured by EAST as previously described. 37 All samples were run in the same experiment.
| Cytokine quantification
Splenocytes (4 9 10 6 spleen cells/mL) were seeded in 96-well cell culture plates in complete medium (RPMI-1640 supplemented with 10% FBS, 100 U/mL penicillin, and 100 lg/mL streptomycin) and 
| Cell isolation from gut and sublingual mucosa
Cells were isolated from the lamina propria (LP) of the oral mucosa or small bowel as described by Di Sabatino et al. 38 In brief summary, Gating strategy for dendritic cell characterization was as follows:
First, we plotted SSC-H vs FSC-H followed by S CD11c vs MHC II I-A/I-E (eBioscience, UK) dot plot.
2.6.6 | Treg purification and transfer to na€ ıve mice and hypersensitivity symptoms were recorded with an accompanying skin test also being carried as described. 
| Statistical analysis
Experimental values were expressed as means AE SD, and statistical significances between groups were evaluated using Mann-Whitney U test, or ANOVA followed by post hoc analysis with Bonferroni or Dunn 0 s comparison test. P values were considered significant if P < .05; P < .01; P < .001, and analysis was performed using GraphPad 5 software (San Diego, CA).
3 | RESULTS
| Administration of IL-2C ameliorates symptoms and reduces skin mast cell degranulation in sensitized mice
We tested the effect of the sublingual administration of CMP, CMPsl, IL-2 ip, and CMPsl combined with IL-2Cip in IgE-sensitized SMALDINI ET AL. These findings demonstrated that sensitized mice that received the combined SLIT reduced in the clinical score (P < .05), skin test, and foot swelling (P < .01) faster and more efficiently than mice that received only SLIT.
| Systemic Th2 immune response is effectively suppressed with treatments
To elucidate on the immunological response that mediates the control of food allergy, Th2-mediated mechanisms were analyzed. We first observed that CT-driven sensitization to CMP induced a per group) with similar results. Data are expressed as means AE SEM. Statistical significance was assessed using two-way ANOVA (*P < .05; **P < .01; ***P < .001) for comparison with sensitized mice (CMP+CT), or Mann-Whitney for comparison between SLIT and combined SLIT (#P < .05) SMALDINI ET AL.
| 889 significant increase in serum CMP-specific IgE, which was reversed after the first round of treatment (day 76) with CMP sl (P < .05) and CMP sl +IL-2C ip (P < .01) ( Figure 1D ). Furthermore, we observed that IL-2C alone did not suppress IgE secretion after the first round of treatment. Nevertheless, the analysis of serum-specific IgE after the second round of treatments (day 110) revealed a significant reduction in antibody secretion with all treatments, CMP sl +IL-2C ip being the most efficient desensitization protocol. Moreover, IL-5, a prototype type 2 cytokine, was substantially inhibited from spleen cells in animals treated with IL-2C and CMP sl +IL-2C ip (P < .001), and it was suppressed with CMP sl (P < .01) after the first round of treatment.
The second round of treatment sustained the inhibition of IL-5 secretion with CMP sl +IL-2C ip , whereas CMP sl induced a more profound effect ( Figure 1E ). Controls showed no induction of splenocyte IL-5 secretion in mice that received CMP, whereas high levels of the cytokine were detected in the supernatants of cells from sensitized mice (administered with PBS sl ). No changes in IFN-c levels were observed in all conditions (data not shown). These findings suggest a more effective attenuation of the Th2 sensitization in allergic mice when treated with combined SLIT.
| Treatments induced regulatory cytokines and
Tregs in the intestinal lamina propria (Figure 3A) . Interestingly, the abrogation of I-A/I-E high CD11c + myeloid cells was specific of the buccal mucosa ( Figure 3B ).
| The protective effect of CMP+IL-2C
treatment initiated in the oral mucosa and correlated with the induction of suppressive Tregs
In assessing the immunological mechanism underlying the suppression of food allergy, a treatment with CMP sl +IL-2C ip was designed to purify and characterize Tregs ( Figure 4A ). We observed that 2 administrations of CMP sl followed by 3 systemic boosters with IL- 
| DISCUSSION
Genetic and immunological evidence proposes that the pathogenesis of allergic disease is closely related with a breakdown in oral tolerance to foods. The expansion of Tregs balances the immune system, restraining the specific Th2 cell response at mucosal sites. 40 Currently, interesting research is being focused on developing therapies that modify the allergic immune response through the restoration of tolerance in patients. 41, 42 The oral allergen-specific approach seems . Na€ ıve mice were transferred with sorted cells, were subsequently sensitized with CMP and CT, and finally challenged intragastrically. D, Symptoms scored after the intragastric challenge. E, Skin test and swelling of footpad in the different group of mice. Data are expressed as means AE SEM. Statistical significant differences between the groups were determined using Mann-Whitney test (*P < .05; **P < .01) [Colour figure can be viewed at wileyonlinelibrary.com] to be promising with a recent study that compared oral and sublingual immunotherapies showing that the controlled sublingual administration of allergens is safer, although less effective, compared to oral immunotherapy. 43, 44 Although SLIT has proven to be clinically effective in asthma and rhinoconjunctivitis, in food allergy it has been proposed the allergen should be administered accompanied with a pro-tolerogenic adjuvant for the induction of robust tolerance. 45 Another therapeutic option is combined therapies. Bonnet et al 36 
